Pharmacodynamics of Elocon

Mometasone - GCS, which has anti-inflammatory, antipruritic and antiexudative action. GCS induce the release of proteins that inhibit phospholipase A2 and are collectively known as lipocortins, which control the biosynthesis of inflammatory mediators such as PG and LT by inhibiting the release of their common precursor, arachidonic acid.

Pharmacokinetics

Absorption of the drug Elocon® Lotion (0.1% solution for external use) is negligible. 8 hours after application to intact skin (without occlusive dressing), about 0.7% is found in the systemic circulation.

Indications of the drug Elocon® Lotion

Inflammation and itching in dermatoses amenable to GCS therapy (including psoriasis), with damage to the hairy areas of the skin (for the treatment of other skin areas, Eloconcan be used® ointment and Elocon® cream).

Contraindications

• Hypersensitivity to any component of the drug or to GCS;
• rosacea;
• perioral dermatitis;
• bacterial, viral (Herpes simplex, chickenpox, Herpes zoster) or fungal skin infection;
• tuberculosis;
• syphilis;
• post-vaccination reactions;
• children under 2 years of age;
• pregnancy (treatment of large areas of the skin, long-term treatment);
• lactation period (use in large doses and / or for a long time).

With care:

• application to face and intertriginous skin;
• the use of occlusive dressings;
• treatment of large areas of skin and / or long-term treatment (especially in children).

Application during pregnancy and lactation

The safety of the use of mometasone furoate during pregnancy and lactation has not been studied.

GCS penetrate the placental barrier. Long-term treatment and the use of large doses during pregnancy should be avoided due to the threat of negative effects on the development of the fetus.

GCS are excreted in breast milk. In the case of the intended use of GCS in large doses and / or for a long time, breastfeeding should be stopped.

Application during pregnancy and lactation

The safety of the use of mometasone furoate during pregnancy and lactation has not been studied.

GCS penetrate the placental barrier. Long-term treatment and use in high doses during pregnancy should be avoided due to the risk of negative effects on fetal development.

GCS are excreted in breast milk. If you need to use GCS in high doses and / or for a long time, you should stop breastfeeding.

Use in children

Thewith caution preparation should be appliedto the face and intertriginous skin, use occlusive dressings, and also apply on large areas of the skin and / or for a long time (especially in children).

Due to the fact that in children the value of the ratio of surface area and body weight is greater than in adults, children are at greater risk of suppression of the function of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome when using any local GCS.

Prolonged use of GCS in children can lead to impaired growth and development.

Children should receive the minimum dose of the drug sufficient to achieve the effect.

Special instructions

When applied on large areas of the skin for a long time, especially when using occlusive dressings, it is possible for GCS to enter the systemic circulation and the development of systemic action of GCS. Given this, patients should be monitored for signs of suppression of the function of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome.

Avoid getting the drug in the eyes.

Propylene glycol, which is part of the drug, can cause irritation at the site of application. In such cases, you should stop using Elocon and prescribe appropriate treatment.

It should be borne in mind that GCS can change the manifestations of some skin diseases, which can complicate the diagnosis. In addition, the use of GCS can be the cause of delayed wound healing.

With prolonged therapy with GCS, a sudden cessation of therapy can lead to the development of rebound syndrome, manifested in the form of dermatitis with intense redness of the skin and a burning sensation. Therefore, after a long course of treatment, the drug should be withdrawn gradually, for example, by switching to an intermittent treatment regimen before completely stopping it.

Use in Pediatrics

Due to the fact that the ratio of surface area to body weight in children is greater than in adults, children are at greater risk of suppression of the function of the hypothalamic-pituitary-adrenal system and the development of Cushing's syndrome when using any local GCS.

Prolonged use of GCS in children can lead to impaired growth and development.

Children should receive the minimum dose of the drug sufficient to achieve the effect.

Overdose

Symptoms: suppression of the function of the hypothalamic-pituitary-adrenal system, including secondary adrenal insufficiency.

Treatment: symptomatic, if necessary - correction of electrolyte imbalance, drug withdrawal (with prolonged therapy - gradual withdrawal).

Drug Interactions

There is no data on the interaction of Elocom with other drugs.

Side effects

Local reactions: rarely - irritation and dryness of the skin, burning sensation, itching, folliculitis, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, accession of a secondary infection, skin maceration, signs of skin atrophy, striae, prickly heat; less than 1% - the formation of papules, pustules.

When using external forms of GCS for a long time and / or for the treatment of large areas of the skin, or using occlusive dressings, especially in children and adolescents, side effects characteristic of systemic GCS, including adrenal insufficiency and Cushing's syndrome, may occur